الفهرس 
Expression of CIP2A in adult acute myeloid leukemia patients
ContentsOnly 14 pages are availabe for public view
 |  | from | 171 |  |  |
| | | from | 171 | | |
Abstract
Background: Genetic variations are one of the important factors in the development of acute leukemia. CIP2A is a newly identified inhibitor of PP2A. It can stabilize c-Myc and promote anchorage-independent cell growth and tumor formation.CIP2A is over-expressed in some solid tumors although its expression in acute myeloid leukemia (AML) is still unknown. Aim of the study: To detect the expression of CIP2A gene in Egyptian acute myeloid leukemia (AML) patients and to determine the function of its overexpression in the development and/or progression of myeloid leukemia. Patients and Methods:The study was carried out on 60 patients with de novo AML (as a patient group), as well as 22 bone marrow samples from normal healthy individuals (as a control group). Using Quantitative real time PCR, we analyzed the expression of CIP2A as a new candidate gene implicated in adult patients with acute myeloid leukemia. Results: According to our study, 21 out of 60 patients (35%) with newly diagnosed AML had elevated expression of CIP2A mRNA while 39 patients (65%) had normal CIP2A mRNA expression. No statistical significant difference was found between patients and control group. Conclusions: These results suggest that several Egyptian AML cases had low levels of CIP2A, even below normal BM. Additional studies are needed to elucidate the meaning of this finding